Acquired Thrombotic Thrombocytopenic Purpura
📧 Sign up to get email alerts when something new happens for Acquired Thrombotic Thrombocytopenic Purpura.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP [Phase 2]
A Phase 2 trial evaluating a personalized caplacizumab regimen guided by ADAMTS13 activity in adults with acquired thrombotic thrombocytopen…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura
This clinical trial evaluates improved immunologic and molecular methods for diagnosing and following up patients with acquired thrombotic t…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) [Phase 2, Phase 3]
This update reports completion of Phase 2/Phase 3 trials of caplacizumab in Japanese patients with acquired thrombotic thrombocytopenic purp…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
The update reports on platelet response to caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura, based on a complet…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases [Phase 2]
Phase 2 clinical trial update on BCMA-CD19 CAR-T therapy for refractory autoimmune diseases, currently recruiting. The study targets several…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
This trial update presents a retrospective analysis of the effectiveness of caplacizumab in treating acquired thrombotic thrombocytopenic pu…
-
FDA approval · 2024-04-11FDA Approved: CABLIVI — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for Cablivi (caplacizumab) submitted by Genzyme, resulting in changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2022-12-01Clinical Trial Update: Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) [Phase 2]
Phase 2 trial of rADAMTS-13 (SHP655) for acquired thrombotic thrombocytopenic purpura (aTTP) has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-11-22Clinical Trial Update: Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) [Phase 3]
Follow-up study for patients who completed the Phase 3 HERCULES trial (ALX0681-C301) in acquired thrombotic thrombocytopenic purpura has com…
-
FDA approval · 2020-12-16FDA Approved: CABLIVI — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for CABLIVI (caplacizumab) filed by Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2019-07-17Clinical Trial Update: A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP) [Phase 2]
Phase 2 clinical trial update for anfibatide in acquired thrombotic thrombocytopenic purpura (TTP) is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) [Phase 2]
Phase 2 trial evaluating an anti-von Willebrand Factor nanobody for safety and efficacy in acquired thrombotic thrombocytopenic purpura has …
-
CLINICAL_TRIALS trial_result · 2019-05-22Clinical Trial Update: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura [Phase 3]
Phase III trial of caplacizumab in acquired thrombotic thrombocytopenic purpura has completed with results posted.
-
FDA approval · 2019-02-06FDA Approved: CABLIVI — Original Application (Genzyme Corporation)
FDA approved CABLIVI (caplacizumab) from Genzyme for the treatment of adults with acquired thrombotic thrombocytopenic purpura.